Company highlights recent progress on clinical DARPin® compounds, its oncology research strategy and to discuss the strategic collaboration with Amgen on MP0310.
Read More
Molecular Partners and Amgen announced a collaboration and license agreement for the clinical development and commercialization of MP0310 (FAP x 4-1BB). MP0310 is a preclinical molecule designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via 4-1BB (immune modulator).
Molecular Partners announces the continued progress of its pipeline of proprietary therapeutic product candidates in oncology and immuno-oncology, as well as in ophthalmology together with its partner Allergan on the company’s R&D Day in New York.
Molecular Partners will present new data on its immuno-oncology pipeline at upcoming scientific conferences.
Molecular Partners published its Interim Management Statement for the period ending September 30, 2018, highlighting positive phase 3 efficacy data for abicipar, the ongoing clinical trials for MP0250 in oncology as well as further advancement of the immuno-oncology pipeline of the company.
Phase 3 safety and efficacy data of abicipar in patients with neovascular Age-related Macular Degeneration (nAMD) were presented at the American Academy of Ophthalmology (AAO) conference in Chicago. These data underline that abicipar has the potential to become the first fixed 12-week anti-VEGF therapeutic.
Molecular Partners announces its unaudited financial results for the first half-year 2018, including promising updated data on the phase 2 trial of its lead oncology asset MP0250 and the positive phase 3 topline data for abicipar, as announced on July 19, 2018 by the company’s strategic partner Allergan.
Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials for Abicipar pegol 8 and 12-week Regimens for the Treatment in Patients with Neovascular Age-Related Macular Degeneration
Molecular Partners announces the appointment of PamelaTrail as Chief Scientific Officer and Michael Stumpp as Chief Operating Officer of the company.
Molecular Partners presents updated preliminary results from its ongoing Phase 2 study of MP0250 at the European Hematology Association (EHA) in Stockholm.
